In this episode of "The Top Line," we talk with Fierce’s Andrea Park and Gabrielle Masson about the latest from the American Diabetes Association's annual conference. We also cover a statement about transgender care, light therapy, and the rest of the week's headlines. 

To learn more about the topics in this episode:
'Podnosis': Medicaid eligibility determinations, healthcare for the LGBTQ+ community
Introducing the Fierce 50: Honoring healthcare and biopharma champions fighting for patient care
Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle
Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect
UPDATE: Lilly's next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz
Let there be light: Scientists report new progress in quest to treat afib with optogenetics
UK's flagging clinical trial sector faces fresh challenge as National Cancer Research Institute set to close
Biotech leaders protest 'actively harmful' bans on gender-affirming care
Know Labs unveils first prototype of portable, noninvasive glucose monitor
Embecta dives deeper into Type 2 diabetes tech with Tidepool team-up
Fitterfly's diabetes digital therapeutic cuts blood sugar, weight in real-world trial

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

We’d love to hear from you! If you have a comment about this podcast or if you have a tip for a future episode of The Top Line, you can reach us at this link.

In this episode of "The Top Line," we talk with Fierce’s Andrea Park and Gabrielle Masson about the latest from the American Diabetes Association's annual conference. We also cover a statement about transgender care, light therapy, and the rest of the week's headlines. 
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercehealthcare.com/payers/podnosis-medicaid-eligibility-determinations-healthcare-lgbtq-community">'Podnosis': Medicaid eligibility determinations, healthcare for the LGBTQ+ community</a></li>
<li><a href="https://www.fiercepharma.com/fierce-50/introducing-fierce-50-honoring-healthcare-and-biopharma-champions-fighting-patient-care">Introducing the Fierce 50: Honoring healthcare and biopharma champions fighting for patient care</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/lilly-links-oral-obesity-drug-15-weight-loss-setting-bar-pfizer-blockbuster-battle">Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-19-weight-loss-high-dose-patients?utm_medium=email&amp;utm_source=nl&amp;utm_campaign=LS-NL-FierceBiotech&amp;oly_enc_id=8197B1373267B5C">Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/lillys-next-obesity-drug-just-cut-average-58-pounds-prompting-all-phase-3-blitz">UPDATE: Lilly's next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz</a></li>
<li><a href="https://www.fiercebiotech.com/research/let-there-be-light-scientists-report-new-progress-quest-treat-afib-optogenetics">Let there be light: Scientists report new progress in quest to treat afib with optogenetics</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/uks-national-cancer-research-institute-closing-due-lack-funding">UK's flagging clinical trial sector faces fresh challenge as National Cancer Research Institute set to close</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/biotech-leaders-protest-actively-harmful-bans-gender-affirming-care">Biotech leaders protest 'actively harmful' bans on gender-affirming care</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/know-labs-unveils-first-prototype-portable-noninvasive-glucose-monitor">Know Labs unveils first prototype of portable, noninvasive glucose monitor</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/embecta-dives-deeper-type-2-diabetes-tech-tidepool-team">Embecta dives deeper into Type 2 diabetes tech with Tidepool team-up</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/fitterflys-diabetes-digital-therapeutic-cuts-blood-sugar-weight-real-world-trial">Fitterfly's diabetes digital therapeutic cuts blood sugar, weight in real-world trial</a></li>
</ul>
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
We’d love to hear from you! If you have a comment about this podcast or if you have a tip for a future episode of The Top Line, you can <a href="https://airtable.com/shrw4pdgxyypwLWkX">reach us at this link.</a>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement